Auro Vaccines - Nipah

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:1000 publications

Grant number: N/A

Grant search

Key facts

  • Disease

    Nipah and henipaviral disease
  • start year

    2020
  • Known Financial Commitments (USD)

    $25,000,000
  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)
  • Principal Investigator

    N/A

  • Research Location

    India
  • Lead Research Institution

    Auro vaccines & PATH
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Pearl River, NY, USA, Seattle, WA and Oslo, Norway, March 13, 2020 'Äî A Phase 1 clinical study of a Nipah virus vaccine candidate (HeV-sG-V) is underway. This trial marks the first time a vaccine developed to prevent Nipah virus infection will be studied in humans. No vaccines currently exist to protect against the deadly virus and the only treatment available is supportive care. CEPI first announced up to $25 million of funding for this programme in May, 2018. The Phase 1 trial is a randomised, placebo-controlled, dose-finding study to investigate the safety, tolerability and immunogenicity of HeV-sG-V Nipah vaccine candidate. The study, sponsored by Auro Vaccines LLC and led by PATH, is being conducted at the Cincinnati Children's Hospital Medical Center in Cincinnati, USA. More information about the trial can be found using the ClinicalTrials.gov Identifier, NCT04199169. The HeV-sG-V Nipah vaccine candidate The Nipah virus vaccine programme is the result of a global partnership between Auro Vaccines, PATH and CEPI. The vaccine was originally developed by Dr. Christopher Broder and Dr. Katharine Bossart at the US government's Uniformed Services University of the Health Sciences (USU, Bethesda, MD). The HeV-sG-V Nipah vaccine candidate is a recombinant subunit vaccine that contains a portion of the G glycoprotein of Hendra virus, a henipavirus closely related to Nipah. HeV-sG-V has been shown in preclinical studies to protect against Nipah virus and Hendra virus and has been licensed to Auro Vaccines from The Henry M. Jackson Foundation for the Advancement of Military Medicine, (HJF) through the USU/HJF Joint Office of Technology Transfer, to develop the human vaccine. Auro Vaccines, with the support of CEPI, will be sponsoring the Phase 1 study; PATH, an international global health organisation, is leading clinical operations; and CEPI is funding the programme through Phase 2 clinical study. Under the terms of the Framework Partnering Agreement originally awarded by CEPI for the collaboration among the three parties, Emergent BioSolutions Inc. has provided contract development and manufacturing services out of its Gaithersburg and Baltimore facilities in Maryland to produce the Phase 1 clinical trial material. Emergent, through a separate agreement with Auro Vaccines, has an exclusive option to license and to assume control of development activities for the Nipah virus vaccine candidate.

Publicationslinked via Europe PMC

Last Updated:4 hours ago

View all publications at Europe PMC

Nucleosome spacing can fine-tune higher-order chromatin assembly.

Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers.

Environmental variability shapes the representational format of cultural learning.

The cytosolic branched-chain amino transferase 1 (BCAT1/BCATc) inhibitor reduces mitochondrial capacity in a myotube model of insulin resistance.

An aminosterol breaks the autocatalytic cycle of Aβ<sub>42</sub> aggregation and protects cell membranes from its soluble aggregates.

Directional sensitivity of the auriculomotor system to transient central and lateralized auditory stimuli.

Framework for bias evaluation in large language models in healthcare settings.

Distinguishing PEX2 and PEX16 gene variant severity for mild, severe, and atypical peroxisome biogenesis disorders in Drosophila.